However, while preclinical studies have assessed the effects of LMP7 inhibition in models of colorectal cancer [18] and prostate cancer [19], the value of LMP7 inhibitors in other solid tumors with high unmet therapeutic need has not been extensively characterized. Here, PSMB8 is linked to prostate carcinoma.